Introduction:
Tenascin-C is a large extracellular matrix (ECM) glycoprotein that has been found to be prominent in embyrogenesis, angiogenesis, wound healing and tumorogenesis [1, 2] There has been significant debate in the literature regarding the adhesive vs. anti-adhesive properties of tenascin-C and the role it plays in cell-matrix interaction and cell mobility. Fibronectin is a prominent ECM glycoprotein that is known to have cell-adhesive properties. Several laboratories have shown tenascin-C to inhibit cell binding to fibronectin [1] . However, recent elucidation of several splice variants of tenscin-C has shed light on the possibility of adhesive/anti-adhesive properties of the varying splice products and their effect on cell-matrix adhesion [3] We have previously examined the in vitro tenascin-C splicing patterns of chondrocytes and chondrosarcoma cells. We determined that the articular chondrocytes secrete predominantly the smaller 220 kDa splice variant and incorporate the protein into the ECM. In contrast, the tumor cells secrete predominantly the large 320 kDa splice variant which is released into the media without incorporation into the ECM.
The purpose of this study was to determine the in vitro adhesive vs. antiadhesive properties of the two major tenascin-C splice variants and their effects on chondrosarcoma cell adhesion to fibronectin. We hypothesize that the distinct tenascin-C splicing pattern of malignant chondroid cells may play a role in cell-matrix interaction, cell migration and metastasis.
Methods: Enzyme-Linked Immunoabsorbence Assay (ELISA):
Fibronectin was diluted in phosphate-buffered saline (PBS) to a concentration of 2 µg/ml. Tenascin small (220 kDa) and large (320 kDa) expression proteins were diluted in PBS to a concentration of 10 µg/ml. Ninety-six well immunoadehsive plastic plates were coated overnight at 4 0 C with the test protein. The wells were rinsed with PBS and two wells coated with fibronectin underwent a second overnight coating at 4 0 C with tenascin (220 kDA or 320 kDa). In experiment A, the wells were blocked for 1 hour at 37 0 C with 1% bovine serum albumin (BSA) in between protein coats. In experiment B, the wells were blocked following the second protein coat. Negative control wells included BSA coating only.The wells were rinsed with PBS and incubated for 2 hours at 37 0 C in a 1/2000 solution of anti-tenascin terminal knob rabbit polycolonal antibody. The wells were rinsed with Tween-PBS (PBS-T) and incubated for 1 hour at 37 0 C with a secondary anti-rabbit IgG HRP conjugated antibody. The antibody binding was detected with HRP color-developing substrate and read at 490 nm.
Cell Adhesion Assay: Ninety-six-well plates were prepared as above. The phenotypically stable chondrosarcoma cell line, JJ012, was provided by Dr. Joel Block. The cells were cultured in a monolayer in basal media supplemented with 10% fetal bovine serum (FBS), split and replated at half-confluence two days prior to the assay. The cells were released from the substratum with 1mg/ml trypsin, washed several times in 0.5% trypsin inhibitor, and diluted in media to a concentration of 1X10 6 cells/cc. At total of 1X10 5 cells (100 µl) were added to each well and incubated for 1 hour at 37 0 C. The wells were rinsed with PBS and a hexosaminidase substrate was added to the wells and incubated for 3 hours at 37 0 C. The hexosaminidase product was developed with 50mM glycine buffer with 5mM EDTA and read at 405 nm wavelength.
All experiments were performed in triplicate and on three separate occasions. Data analysis was performed using t-test comparison of means (Microsoft Excel). A value P<0.05 was considered significant.
Results:
ELISA: In experiment A (BSA between coats) both tenascin splice variants were detected on plastic alone, and the 220 kDa protein was found to bind to fibronectin, whereas the 320 kDa did not ( Figure 1A) . In experiment B (BSA after both coats) both tenascin proteins were found to bind to the fibronectinplated wells ( Figure 1B) . These results indicate that the plastic left uncovered and unblocked in the fibronectin wells served as an adhesion substrate for the 320 kDa fragment. We observed that the tenascin 220 kDa protein binds to plastic and fibronectin, whereas the 320 kDa protein binds to plastic only. 
Cell Attachment Assay:
In experiment A , JJ cell attachment to fibronectin was unaffected in the wells coated with the 320 kDa fragment, but was significantly inhibited (P<0.01) in the wells where the 220 kDa protein was bound to fibronectin (Figure 2A ) . In contrast, in experiment B, the attachment of the 220 kDa protein in the fibronectin wells significantly increased JJ cell adhesion (P<0.05) ( Figure 2B ). 
Discusison:
In this series of in vitro experiments, we found that the small tenascin splice variant is able to bind to fibronectin, whereas the larger splice variant does not. This phenomenon has been observed previously [3] and may be due to the steric blocking of the fibronectin binding site by the large glycosylated variable splicing region that is not present in the 220 kDa protein [2] . In addition, we found that the binding of the 220 kDa fragment to fibronectin inhibited cell attachment to fibronectin. It is possible that cell-binding sites on fibronectin are blocked by the binding of the 220 kDa protein to fibronectin. However, the presence of the 220 kDa fragment, when bound to plastic, has an additive adhesive effect for cells to the fibronectin substrate. Therefore, the role of the small tenascin splice variant may be adhesive or anti-adhesive, depending on the substrate to which it is bound. The large 320 kDa splice variant was not found to have adhesive properties. We have previously shown that articular chondrocytes produce significantly more of the 220 kDa tenascin variant than do malignant chondroid cells. We therefore propose that this molecule plays a role in cell-matrix interaction, possibly anchoring the cell to the matrix and preventing cell migration towards blood vessels and metastasis.
